3B Blackbio (532067)

FairStock Score: 59/100 — STEADY

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Exceptional growth: sales up 98.31% and profit up 62.16%.
• High profitability with latest quarter net margin around 44%.
• Strong returns: ROE 20.43% and ROCE 25.75%.
• Low PEG ratio of 0.25 suggests growth is not fully priced in.
• Piotroski F-Score of 7/9 indicates sound financial health.

Concerns

• Trading at ₹1024.20, below its 52-week low of ₹1110, showing negative price momentum.
• Very high net margins may be unsustainable as competition and costs rise.
• Dividend yield only 0.30%, so total return hinges entirely on growth.
• Promoter holding and debt/equity data are not disclosed, limiting governance and leverage assessment.

AI Analysis

When I look at 3B Blackbio, I see a business growing at a pace that would make most companies dizzy. Sales up 98.31% and profits up 62.16%, with a latest quarter showing ₹50 Cr in sales and ₹22 Cr in net profit. That is a 44% net margin, which is exceptional for any healthcare service provider. As Graham taught, growth is wonderful only when it is bought at a sensible price. At a P/E of 20.20 and a PEG of 0.25, the market is paying very little for this growth. The Piotroski F-Score of 7/9 tells me the underlying financial health is solid, and with zero reported debt, the balance sheet does not keep me awake at night. Return on equity of 20.43% and ROCE of 25.75% are well above what I expect from an average Indian business. However, I must be cautious. A price of ₹1024.20 is below the 52-week low of ₹1110, which suggests the market has already turned skeptical. High growth rates often invite competition, and a 44% net margin is a high bar to sustain. The dividend yield of 0.30% means I am relying entirely on capital appreciation and reinvestment. Also, with promoter holding not disclosed and debt/equity marked not available, I cannot complete my usual checklist of quality and governance. This is a fast grower, not a stalwart yet. If the growth continues and margins hold, the current valuation is attractive. But I would want to see the next few quarters before treating this as a core holding. The score of 59/100 says steady, not spectacular. I will watch it, but I will not chase it blindly.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer